Skip to main content
Fig. 2 | BMC Medicine

Fig. 2

From: Heterogeneous response and progression patterns reveal phenotypic heterogeneity of tyrosine kinase inhibitor response in metastatic renal cell carcinoma

Fig. 2

Example of individual lesion response assessments within one patient. Lesion size on each CT scan relative to the size on the baseline scan was calculated until RECIST-defined progression. Based on the best response that was achieved over the treatment period, each lesion was categorised either as a Responding Lesion (RL, 30% or greater decrease in diameter compared to baseline), Progressing Lesion (PL, 20% or greater increase in diameter compared to baseline) or Stable Lesion (SL, all remaining lesions). The emergence of new lesions (NL) was also recorded

Back to article page